Davies J, Casey J, Li C, Crowe A V, McClelland P
Renal Unit, Wirral Hospital NHS Trust, Merseyside, UK.
EDTNA ERCA J. 2005 Apr-Jun;31(2):75-8. doi: 10.1111/j.1755-6686.2005.tb00398.x.
Urokinase and streptokinase are commonly used thrombolytic agents for obstructed central venous catheters. Although proven to be efficacious, these agents have the potential to induce fibrin breakdown and streptokinase cannot be used repeatedly due to its allergenic nature. Documented evidence suggests that urokinase is safe and effective (> 70% efficacy for catheter installation) however further evidence points to tissue-type plasminogen activator (rt-PA) achieving as much as 98% success. This study reports on the safety and efficacy of alternative catheter thrombolysis, namely rt-PA and evaluates the efficacy of rt-PA. 20 patients required 57 infusions in 38 lumens between 01/01/02 to 01/09/03. For completely blocked lines rt-PA was infused at 2 mg/hr for 4 hours achieving 85% success rate. For inadequate flow (< 250 mls/min) rt-PA was infused at 1 mg/hr for 4 hours achieving 88% success rate.
尿激酶和链激酶是常用于治疗中心静脉导管阻塞的溶栓剂。尽管已证明这些药物有效,但它们有可能导致纤维蛋白分解,并且由于链激酶具有致敏性,不能重复使用。有文献记载,尿激酶是安全有效的(导管置管成功率>70%),然而进一步的证据表明,组织型纤溶酶原激活剂(rt-PA)的成功率高达98%。本研究报告了替代导管溶栓剂rt-PA的安全性和有效性,并评估了rt-PA的疗效。2002年1月1日至2003年9月1日期间,20名患者在38个管腔中进行了57次输注。对于完全堵塞的导管,以2毫克/小时的速度输注rt-PA 4小时,成功率达到85%。对于血流量不足(<250毫升/分钟)的情况,以1毫克/小时的速度输注rt-PA 4小时,成功率达到88%。